In the p21‐activated protein kinase (PAK) family, we observed a decrease in oncogenic PAK1 expression, while the neuronal marker PAK3, positively correlated with GBM patient survival [47], was upregulated, indicating its potential as a therapeutic target. This evidence concerns the gene PAK1 and glioblastoma.